🔴 Scholar Rock is trading 4% down today after post-approval profit-taking

Scholar Rock is trading 4% down at $47.05 as investors reassess valuation following the FDA approval of ISEMBYLD.

• Barclays downgraded the shares to Equalweight from Overweight on September 15, citing valuation concerns, while raising its price target to $58.
• The decline appears consistent with a post-approval pullback after the September 11 regulatory milestone.
• The broader biotech sector is rising, making sector weakness an unlikely explanation.